Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
Authors
Keywords
-
Journal
Neurodegenerative Diseases
Volume 17, Issue 6, Pages 242-250
Publisher
S. Karger AG
Online
2017-08-09
DOI
10.1159/000478741
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 39-Week Toxicity and Toxicokinetic Study of Ponezumab (PF-04360365) in Cynomolgus Monkeys with 12-Week Recovery Period
- (2018) Gary B. Freeman et al. JOURNAL OF ALZHEIMERS DISEASE
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
- (2018) Stina Tucker et al. JOURNAL OF ALZHEIMERS DISEASE
- The Failure of Solanezumab — How the FDA Saved Taxpayers Billions
- (2017) Chana A. Sacks et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2016 Alzheimer's disease facts and figures
- (2016) Alzheimers & Dementia
- Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
- (2016) Eric R. Siemers et al. Alzheimers & Dementia
- Drug treatments in Alzheimers disease
- (2016) R. Briggs et al. CLINICAL MEDICINE
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies
- (2016) Hamid Reza Amanatkar et al. Expert Review of Neurotherapeutics
- Amyloid Cascade into Clarity
- (2016) Tara M. Weitz et al. IMMUNITY
- Alzheimer's disease
- (2016) Philip Scheltens et al. LANCET
- Failed Alzheimer’s trial does not kill leading theory of disease
- (2016) Alison Abbott et al. NATURE
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Therapeutic strategies for Alzheimer's disease in clinical trials
- (2016) Justyna Godyń et al. Pharmacological Reports
- First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease
- (2016) Marielle Delnomdedieu et al. Alzheimers Research & Therapy
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
- (2016) Rik Vandenberghe et al. Alzheimers Research & Therapy
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies
- (2016) Hamid Reza Amanatkar et al. Expert Review of Neurotherapeutics
- Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
- (2015) Isabelle St-Amour et al. ACTA NEUROPATHOLOGICA
- Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity
- (2015) Kelly R. Bales et al. BRAIN
- Alzheimer's disease and other dementias: advances in 2014
- (2015) Randall Bateman LANCET NEUROLOGY
- Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
- (2015) Enchi Liu et al. NEUROLOGY
- What lessons can be learned from failed Alzheimer’s disease trials?
- (2015) Jeremy Toyn Expert Review of Clinical Pharmacology
- Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?
- (2014) Francesco Panza et al. CURRENT OPINION IN PSYCHIATRY
- Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
- (2014) Francesco Panza et al. Expert Review of Clinical Immunology
- Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
- (2014) Francesco Panza et al. Expert Review of Neurotherapeutics
- Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease
- (2014) Norman Relkin JOURNAL OF CLINICAL IMMUNOLOGY
- Anti-ApoE Antibody Given after Plaque Onset Decreases A Accumulation and Improves Brain Function in a Mouse Model of A Amyloidosis
- (2014) F. Liao et al. JOURNAL OF NEUROSCIENCE
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA)
- (2013) Laurent Pradier et al. Alzheimers & Dementia
- Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
- (2013) Richard Dodel et al. LANCET NEUROLOGY
- Update on current and future novel therapies for dry age-related macular degeneration
- (2013) Ella Leung et al. Expert Review of Clinical Pharmacology
- Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
- (2012) Jungsu Kim et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Sting of Alzheimer's failures offset by upcoming prevention trials
- (2012) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease
- (2011) Sherry L. La Porte et al. JOURNAL OF MOLECULAR BIOLOGY
- Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load
- (2011) Qingyou Li et al. Journal of Neuroimmune Pharmacology
- Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
- (2011) Susann Cattepoel et al. PLoS One
- A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid- Production in Vivo
- (2011) J. K. Atwal et al. Science Translational Medicine
- Pathways linking Aβ and tau pathologies: Figure 1
- (2010) Frank M. LaFerla BIOCHEMICAL SOCIETY TRANSACTIONS
- Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
- (2010) Eric R. Siemers et al. CLINICAL NEUROPHARMACOLOGY
- The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal
- (2009) John Hardy JOURNAL OF NEUROCHEMISTRY
- Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
- (2008) Irina Petrushina et al. Journal of Neuroinflammation
- 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
- (2008) Norman R. Relkin et al. NEUROBIOLOGY OF AGING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started